In the investigation of any new neuromuscular blocking agent, the drug potency (ED 50 , the dose required to produce 50% twitch depression) should be estimated early in the development process. Without this information, an estimate of its clinical margin of safety (the ratio of the ED 50 or ED 95 neuromuscular blocking dose to the ED 50 dose which produces unacceptable cardiovascular or other adverse side-effects) cannot be ascertained. However, because there is considerable patient-to-patient variability in the sensitivity to relaxants, 1 2 the determination of potency with small samples may give misleading results. The development of any new drug is an expensive undertaking, and the recruitment of experimental subjects is timeconsuming and costly. When obtaining data, a balance must be struck between scientific rigour and unnecessary expenditure. Surprisingly, there is little consensus in the neuromuscular literature on how large a sample size needs to be before these conflicting demands are both reasonably satisfied. The consensus paper 'Good Clinical Research Practice in Pharmacodynamic Studies of Neuromuscular Blocking Agents' (GCRP) which represents the most current thinking for clinical investigators in this area is essentially silent on this subject. 3 The comment 'An adequate sample size should be determined before carrying out the study to prevent any waste of time and resources on an inconclusive investigation' although obviously correct is not particularly helpful.
When planning a protocol for a new non-depolarizing agent, a pre-requisite for approval by most Institutional Review Boards (IRBs) is an estimate of required sample size as determined by power analysis. In our review of the neuromuscular literature, dose -response studies that include an a priori power analysis are few and far between and the methodology used is usually far from transparent. 4 Thus, we had no theoretical guidance as to how to proceed or defend any given sample size we might select. We suspect that the failure of most investigators to use power analysis is because the calculations require some knowledge of the variability around the mean, that is, the standard deviation (SD) of the sample or the coefficient of variation (COV) which is the SD divided by the arithmetic mean. Although the 95% confidence limits of the mean ED 50 value are often reported, confidence limits are a measure of the reliability of the mean value and not of individual data dispersion. There are very few published data describing the SD or COV for the ED 50 of commonly used neuromuscular blocking agents. The method most commonly used to determine neuromuscular potency (least-squares regression analysis) does not lend itself to providing this information. However, once the best-fit slope of the dose -response relationship is determined by regression analysis, this value can be substituted for g in the Hill equation. 5 6 If this is done, the ED 50 for each individual subject can be estimated. Consequently, calculating the average ED 50 and its SD and COV is an easy next step. With this information, estimating neuromuscular doseresponse sample size based on conventional power analysis becomes a relatively simple procedure. When reviewing data from a recent publication 7 in which we re-examined the dose -response relationships of succinylcholine, rocuronium, rapacuronium, and cisatracurium, we noticed that the COV of these compounds appeared to be relatively constant from agent to agent. We hypothesized that if this is so, then sample size recommendations for these agents might be generally applicable to other neuromuscular blocking drugs as well. Therefore, we examined data from our files for four additional agents (pipecuronium, pancuronium, atracurium, and vecuronium) to extend our observations on the individual variability in the response to neuromuscular blocking agents. We believe that this information will be of use to investigators in the design of future dose -response studies. In addition, our methodology provides a power analysis-based rationale for determining the sample size when performing dose -response studies of neuromuscular blocking compounds.
Methods
The present protocol was approved by the Human Subject Review Committee at Weill Cornell Medical College. All patients consented to participate in the earlier IRB-approved studies from which the data were obtained. The methodology used in obtaining our dose -response data has been previously described in detail. 2 i.v. Tracheal intubation was accomplished without the use of neuromuscular blocking agents. Anaesthesia was maintained with nitrous oxide (65 -70% inspired), a propofol infusion, and opioid supplements as needed. Ventilation was controlled, and end-tidal carbon dioxide was maintained at 4.5-5.3 kPa. The indirectly evoked integrated compound action potential of the first dorsal interosseous muscle to supramaximal stimulation of the ulnar nerve at the wrist was measured and recorded using an NMT 221 monitor (Datex, Tewksbury, MA, USA). Single stimuli at 0.10 Hz were administered during the period of observation, and twitch depression was continuously recorded. Control twitch height was established after a 15-20 min period of baseline stabilization. Immediately after baseline calibration, a single dose of relaxant was administered.
The first subject in each group received a bolus estimated from published peer-reviewed data to approximate an ED 50 . Using the Hill equation with a postulated slope of 4.50 -4.75, the subject's individual ED 50 was then estimated. The second subject received a dose which equalled the calculated ED 50 for Patient 1. Patients 3-5 were given a dose that approximated the average estimated value of the ED 50 s of the subjects which preceded them. In a similar manner, Patients 6-10 were administered a dose based on the results of the earlier subjects calculated to achieve 20% twitch depression. The next five subjects received doses which approximated the average estimated value of the ED 80 . In the remaining patients, doses of each blocking drug were selected to provide essentially equally distributed increments in the range estimated to span responses from 15% to 95% twitch depression. We observed 100% block in two patients in the succinylcholine and rapacuronium groups. These data points were recorded as an effect of 99.5% when entered into the Hill equation. We did not encounter any 0% responses. In each group, once all the data points were collected, the slope of the best-fit line of regression was used to recalculate the ED 50 for each subject and finally the mean ED 50 and its SD using the Hill equation.
Fifty ASA I adult patients undergoing elective surgery received cisatracurium. 8 Anaesthesia was induced with midazolam, propofol, fentanyl, and 70% nitrous oxide in oxygen and was maintained with a continuous infusion of propofol and nitrous oxide (70% inspired) with incremental doses of fentanyl as needed. The trachea was intubated after induction of anaesthesia without the aid of a neuromuscular blocking agent. Ventilation was adjusted to maintain endtidal PCO 2 at 4.3-5.3 kPa. The ulnar nerve was stimulated with supramaximal train-of-four (TOF) stimuli every 12 s using a Myotest peripheral nerve stimulator (Biometer International, Odense, Denmark). The contraction of the adductor pollicis muscle was recorded using a force displacement transducer and a neuromuscular function analyzer (Myograph 2000, Biometer International). The first response of the TOF was considered the twitch height. Cisatracurium was administered after stabilization of the response to indirect muscle stimulation. Each patient received a single bolus of cisatracurium. Ten patients each received a pre-determined dose of 20, 25, 30, 40, or 50 mg kg 21 . Six of the individuals who received 50 mg kg 21 developed 100% blocks.
Forty subjects received pancuronium and 32 pipecuronium using a methodology 9 similar to that outlined above for cisatracurium. Two patients in the pipecuronium group and four in the pancuronium group had 100% twitch depression from an administered dose of relaxant.
Determining sample size All 100% responses were plotted as a 99.5% response when entered into the Hill equation. The mean ED 50 and coefficients of variation were calculated as described above for succinylcholine, rocuronium, rapacuronium, atracurium, and vecuronium.
Statistical analysis
Non-linear regression analysis A best-fit non-linear analysis was performed on the data for each of the eight neuromuscular blocking agents using GraphPad Prism version 5.02 for Windows (GraphPad Software, San Diego, CA, USA). The function used to calculate the ED 50 was 'log dose vs response-variable slope (four parameters)'. This function, a modification of the Hill equation, is based on the following equation: Y¼ Bottom+(Top2Bottom)/(1+10((log ED 50 2X )×Hillslope)). We set the upper constraint (top) as 100% and the bottom as zero. Hillslope is synonymous with the Hill coefficient or g. The software program also provided the confidence limits for the ED 50 and g. Complete twitch depression was entered as 100% effect.
Hill equation
We calculated the ED 50 values (SD) for all eight drugs by this method using the best-fit values for slope (g) determined using non-linear regression. The Hill equation allows the determination of an individual subject's ED 50 and the ED 95 if three pieces of information are provided-the dose of drug administered, the effect produced by that dose, and the slope (g) of the dose -response relationship for that drug. The various forms of this equation may be found in the appendix of Kopman and colleagues. 5 Sample size analysis If the data from our observations can be generalized to other neuromuscular blocking agents, the ED 50 has a COV of 0.15 -0.27. If this is so, then an a priori one-sample two-tailed t-test of the means can be used to predict the required sample size. To compute sample size, one must supply a hypothetical 'true' ED 50 (H 0 ), the degree to which variation (H 1 ) from H 0 is allowed, the SD of the ED 50 , and values for a and power (12b). Using G*Power3 software& 10 
Results
As six of the individuals who received cisatracurium 50 mg kg 21 developed 100% block, we also performed non-linear regression analysis with this dose omitted (n¼40). Calculated COVs for the ED 50 (n¼40 vs n¼50) did not differ by more than 0.5%. The ED 50 values calculated by non-linear regression or using the Hill equation are essentially interchangeable (Table 1 ). Both methods produce values which vary on average by less than 5%. The median value for g was 4.15 (range 3.6-6.1) ( Table 2) , and the median value for the COV was 24.1% (range 15.3 -27.1%). A relatively small increase in the COV can result in large increases in the required sample size ( Fig. 1 and Table 1) .
A major factor in determining the sample size is the magnitude of the allowable error in the estimated ED 50 which the investigator is willing to accept. Assuming a COV of 25%, only 15 subjects need to be recruited if an error of +20% is deemed good enough. For an allowable error of +15%, a sample size of 24 is required. This value rapidly escalates to 50 subjects if an error of only +10% is sought (Table 3 and Fig. 2) 
Discussion
Before power analysis can be implemented, an investigator must have some idea of the variability of the data in his test sample. Most of the information on the degree to which subjects differ in their sensitivity to neuromuscular blocking drugs comes from techniques other than singledose protocols. When a cumulative dose technique is used to determine drug potency, estimates of patient variability are available since the ED 50 for each subject can be determined. Thus, in a comparison of three different population groups, a COV for the ED 50 of rocuronium of between 26% and 32% was reported. 2 Each of their subjects received six incremental doses. A study of 11 subjects receiving vecuronium 11 (five doses per subject) estimated its ED 50 to be 30.4 (SD 8.8) mg kg 21 (COV¼27%), and a study of 50 individuals estimated the ED 50 of atracurium to be 160 (41) mg kg
21
(COV¼25.6%). 12 Patients in these three studies 2 11, 12 received multiple doses, making comparisons with the single-dose technique we used problematic. In addition, the first two studies cited above looked at only a small number of subjects. When drug potency is measured using a single-dose protocol, estimates of the variability of the ED 50 and ED 95 are usually not given, and when reported they are hard to interpret. A single-dose method reported an ED 90 of 0.30 (0.062) mg kg 21 (COV¼21%) for rocuronium, 13 but the method of calculating the value of the SD is not explained. In contrast to regression methods of determining neuromuscular potency, when using the Hill equation, the calculation of the SD or COV of the ED 50 is easily obtained. Although the estimated mean value of ED 50 is not greatly altered by significant changes in the g used, the same is not true for the effect of the slope on the parameter's COV and thus on the sample size. Any increase in the COV results in larger required sample sizes as determined by power analysis. There are at least theoretical reasons to suggest that traditional linear regression analysis is a flawed approach to determining the neuromuscular doseresponse relationship. 7 Probit and logit analyses are meant to handle only quantal responses with binomial error distributions, not continuous data such as the per cent of maximal response. In addition, 0% and 100% responses are undefined when using logit or probit data transformation. We therefore based our recommendations for the sample size on the COVs which were derived from the best-fit slopes as calculated by non-linear regression.
In our calculations of sample size, we chose a COV of 25% as this approaches the maximum value for g we observed using non-linear regression analysis. This value produces a more conservative (larger) estimate of the required sample size than would be obtained using the slope from traditional log dose logit or probit linear regression analysis. When determining the required sample size, one key element is determined by the investigator. How large an error is deemed acceptable? As can be seen from Figure 2 and Table 3 , as few as 15 subjects may be required if an error of +20% in the ED 50 is thought to be tolerable. However, as the allowable error decreases, the required sample size rapidly increases. There is therefore no absolutely 'correct' solution to the problem of what the sample size should be. Every sample size determination represents a compromise between scientific precision and practical logistics.
When determining sample size for neuromuscular doseresponse studies, we suggest that an allowable error of +15% constitutes a reasonable middle ground. An error of this magnitude in dosing is unlikely to have major clinical consequences, yet the sample size requirement (n¼24) should not impose an undue logistical burden on the investigator. Once 30 valid observations have been obtained, the point of diminishing returns has to a large extent been reached. This latter value also allows some leeway for protocol violations, outliers, and technical difficulties. Beyond this sample size, increases in accuracy are unlikely to be of clinical importance.
Before this study, single-dose protocol-derived potency data on the variability (SD of ED 50 ) of even commonly used drugs were extremely sparse. Our data and conclusions can be used in two ways. Investigators can use a COV of 25% when doing power analysis and enter their own values for a, b, and effect size. Alternatively, investigators who accept our figures for these parameters can use the calculated sample sizes from Table 3 or from Figures 1 and 2 directly and use this study in lieu of performing their own power analysis.
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